Rani Therapeutics director awarded 123,600 stock options

Rani Therapeutics director Bailey Vasudev Jaiprakash received a stock option grant covering 123,600 shares of Class A common stock.

Rhea-AI Filing Summary

Rani Therapeutics director Bailey Vasudev Jaiprakash received a stock option grant covering 123,600 shares of Class A common stock. The option was awarded on May 28, 2026 at an exercise price of $0.9515 per share and is held directly.

The option vests in full on the first anniversary of the grant date, subject to the director’s continuous service under the company’s 2021 Equity Incentive Plan. Vesting can occur earlier if Rani Therapeutics holds its next annual stockholder meeting or if a Change in Control occurs, in each case only if continuous service requirements are met. After this grant, the director holds 123,600 derivative securities related to this option.

Insider Trade Summary

Grant/Award: 123,600 shares

Grant/Award 1 txn

Insider Bailey Vasudev Jaiprakash

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy)	123,600	$0.00	$0.00

Holdings After Transaction: Director Stock Option (Right to Buy) — 123,600 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan (the "2021 Plan")) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Plan), each subject to the Reporting Person's Continuous Service through such date.

Key Figures

Option grant size: 123,600 shares Exercise price: $0.9515 per share Shares underlying option: 123,600 shares +2 more

5 metrics

Option grant size 123,600 shares Director stock option granted May 28, 2026

Exercise price $0.9515 per share Conversion or exercise price of the option

Shares underlying option 123,600 shares Underlying Class A common stock

Post-transaction derivative holdings 123,600 derivatives Total derivative securities following transaction

Option expiration date May 27, 2036 Stated option expiration

Key Terms

Director Stock Option (Right to Buy), Class A Common Stock, 2021 Equity Incentive Plan, Change in Control, +1 more

5 terms

Director Stock Option (Right to Buy) financial

"Security title is listed as "Director Stock Option (Right to Buy)""

Class A Common Stock financial

"Underlying security title is identified as "Class A Common Stock""

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

2021 Equity Incentive Plan financial

"Continuous Service is defined in the Company's 2021 Equity Incentive Plan"

Change in Control financial

"Options vest earlier upon a Change in Control under the 2021 Plan"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

Continuous Service financial

"Vesting is subject to the Reporting Person's Continuous Service through the vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did RANI director Bailey Vasudev Jaiprakash receive in this Form 4 filing?

Bailey Vasudev Jaiprakash received a stock option grant for 123,600 shares of Rani Therapeutics Class A common stock. The option was granted as director compensation and allows purchase of shares at a fixed exercise price if vesting conditions are satisfied.

What is the exercise price and size of the RANI stock option grant?

The director stock option covers 123,600 underlying shares with an exercise price of $0.9515 per share. This means the director can buy those shares at $0.9515 once the option vests and is exercised, regardless of the future market price.

When do the newly granted RANI options to Bailey Vasudev Jaiprakash vest?

The options vest in full on the first anniversary of the May 28, 2026 grant date, subject to continuous service. Vesting can occur earlier upon the next annual stockholder meeting or a Change in Control, if continuous service conditions are still satisfied at that time.

How many RANI derivative securities does Bailey Vasudev Jaiprakash hold after this transaction?

After this transaction, the director holds 123,600 derivative securities related to the option grant. These represent the right to acquire 123,600 shares of Class A common stock at the stated exercise price once vesting conditions have been met.

Is this RANI Form 4 transaction a market purchase or sale of shares?

No, this Form 4 reports a grant of a stock option rather than a market trade. It is a compensation-related award with an exercise price of $0.9515 per share and vesting conditions, not an open-market buy or sell of existing shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/01/2026 - 04:09 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bailey Vasudev Jaiprakash

(Last) (First) (Middle)

C/O RANI THERAPEUTICS LLC

2051 RINGWOOD AVE

(Street)

SAN JOSE CALIFORNIA 95131

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Rani Therapeutics Holdings, Inc. [ RANI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$0.9515	05/28/2026		A		123,600		(1)	05/27/2036	Class A Common Stock	123,600	$0	123,600	D

Explanation of Responses:

1. The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan (the "2021 Plan")) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Plan), each subject to the Reporting Person's Continuous Service through such date.

	/s/ Svai Sanford, Attorney-in-Fact	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)